Grantopen🌐 United StatesPAR-25-297

Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)

National Institutes of Health

Details?

Posted: Dec 4, 2024
Response deadline: Nov 5, 2027, 12:00 AM UTC (481d)
Type: Grant
Category: 93.866
Status: open
Buyer: National Institutes of Health
Department: HHS-NIH11
Jurisdiction: United States
Reference #: PAR-25-297

Doc Type: synopsis
Opp Status: posted

Similar open solicitations

NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
United States · Aug 13, 2024
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
United States · Nov 22, 2024
National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U01 Clinical Trial Optional)
United States · Jan 15, 2025
NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
United States · Nov 7, 2024
Institutional Training Programs to Advance Translational Research on Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (T32 Clinical Trial Not Allowed)
United States · Dec 13, 2024
Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)
United States · Nov 18, 2024

Similar past solicitations

Finding similar opportunities…

This listing is a summary from United States's open procurement data. We ingest every field the feed publishes; the full solicitation documents are on the source portal.